Free Trial

Praxis Precision Medicines (PRAX) Competitors

Praxis Precision Medicines logo
$189.99 +27.28 (+16.77%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$187.82 -2.17 (-1.14%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRAX vs. AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, LNTH, and ADMA

Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

Praxis Precision Medicines vs. Its Competitors

Akero Therapeutics (NASDAQ:AKRO) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Praxis Precision Medicines has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A-$252.06M-$2.00-26.92
Praxis Precision Medicines$8.55M467.75-$182.82M-$12.29-15.46

Akero Therapeutics currently has a consensus price target of $73.38, indicating a potential upside of 36.28%. Praxis Precision Medicines has a consensus price target of $218.27, indicating a potential upside of 14.89%. Given Akero Therapeutics' higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akero Therapeutics
1 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.31
Praxis Precision Medicines
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77

In the previous week, Praxis Precision Medicines had 31 more articles in the media than Akero Therapeutics. MarketBeat recorded 38 mentions for Praxis Precision Medicines and 7 mentions for Akero Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.42 beat Akero Therapeutics' score of -0.08 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akero Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Praxis Precision Medicines
7 Very Positive mention(s)
12 Positive mention(s)
14 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Akero Therapeutics' return on equity of -15.84% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Akero TherapeuticsN/A -15.84% -14.59%
Praxis Precision Medicines N/A -60.07%-54.84%

Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500.

Summary

Praxis Precision Medicines beats Akero Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRAX vs. The Competition

MetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.00B$3.44B$6.19B$10.55B
Dividend YieldN/A2.28%5.70%4.81%
P/E Ratio-15.4623.1685.6227.13
Price / Sales467.75499.63615.49134.47
Price / CashN/A46.9237.1060.81
Price / Book7.9510.4112.236.52
Net Income-$182.82M-$52.77M$3.33B$276.93M
7 Day Performance256.72%2.31%1.17%1.93%
1 Month Performance350.00%12.59%6.85%2.19%
1 Year Performance159.55%11.18%58.93%34.62%

Praxis Precision Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRAX
Praxis Precision Medicines
1.8652 of 5 stars
$189.99
+16.8%
$218.27
+14.9%
+159.5%$4.00B$8.55M-15.46110Trending News
Analyst Forecast
Gap Up
High Trading Volume
AKRO
Akero Therapeutics
3.5527 of 5 stars
$53.66
-0.4%
$73.38
+36.7%
+72.4%$4.31BN/A-26.8330Insider Trade
CRNX
Crinetics Pharmaceuticals
4.3745 of 5 stars
$44.43
-1.1%
$74.45
+67.6%
-29.6%$4.23B$1.04M-10.81210Positive News
MENS
Jyong Biotech
N/A$55.70
+0.8%
N/AN/A$4.20BN/A0.0031Gap Down
NAMS
NewAmsterdam Pharma
2.9656 of 5 stars
$37.15
+0.3%
$42.00
+13.1%
+89.0%$4.17B$45.56M-22.934News Coverage
Analyst Forecast
High Trading Volume
KYMR
Kymera Therapeutics
1.0084 of 5 stars
$59.89
+4.7%
$61.26
+2.3%
+28.9%$4.09B$47.07M-17.26170Analyst Forecast
Insider Trade
SRRK
Scholar Rock
4.4717 of 5 stars
$34.28
-13.1%
$48.60
+41.8%
-8.5%$3.79B$33.19M-11.78140Gap Down
High Trading Volume
VKTX
Viking Therapeutics
3.8797 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-49.0%$3.77BN/A-22.1620News Coverage
Upcoming Earnings
MIRM
Mirum Pharmaceuticals
3.5885 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+86.3%$3.65B$336.89M-59.64140Trending News
Analyst Forecast
Analyst Revision
LNTH
Lantheus
4.5327 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-52.4%$3.64B$1.53B14.52700Trending News
Analyst Revision
ADMA
ADMA Biologics
3.6341 of 5 stars
$14.55
+0.1%
$27.67
+90.1%
-9.0%$3.47B$426.45M16.92530

Related Companies and Tools


This page (NASDAQ:PRAX) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners